C.S. Mott Children's Hospital的动态

A new clinical trial will allow Michigan Medicine researchers to study 3D-printed bioresorbable devices aimed at treating children with rare and life-threatening airway condition tracheobronchomalacia. The trial, launched by Michigan Medicine and Materialise, marks a crucial step towards full FDA approval for the innovative devices designed to support the airways of infants with the severest forms of the disease. Tracheobronchomalacia causes the airway to collapse, making breathing difficult and, in severe cases, can be fatal. Currently, infants with this condition often rely on ventilators to survive. “We have established a process that allows us to offer the customized airway splint as a last resort treatment for certain children with no other options but we need more research to make it available on a wider scale,” said trial principal investigator Richard Ohye, M.D., a pediatric heart surgeon at U-M Health C.S. Mott Children’s Hospital, who leads surgical implantation of the device. “We needed a revolutionary innovation to give these babies a chance to survive,” said Mott otolaryngology surgeon Glenn Green, M.D., one of the inventors of the device. Learn more: https://lnkd.in/e6wP9NPi